{"doi":"10.1345/aph.1c473","title":"Atovaquone–Proguanil for Prophylaxis and Treatment of Malaria","abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:</jats:title>\n                    <jats:p>To review the currently available information on atovaquone–proguanil for treatment and prophylaxis of malaria.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:</jats:title>\n                    <jats:p>A MEDLINE search was conducted from 1966 to February 2003 using key phrases Malarone, atovaquone, proguanil, and malaria. Further articles were identified from a manual search of the references of identified articles.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION:</jats:title>\n                    <jats:p>English-language studies with animal and human data evaluating preclinical pharmacology, human studies on pharmacokinetics, and clinical trials were evaluated. Relevant data were extracted from identified articles.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:</jats:title>\n                    <jats:p>Atovaquone–proguanil has been evaluated for treatment of acute, uncomplicated malaria caused by Plasmodium falciparum in 8 clinical trials. In these studies, treatment with atovaquone–proguanil led to a higher (87–100% vs. 72–88%) or equally effective (94–100% vs. 90–100%) cure rate than the comparator antimalarial agents. Atovaquone–proguanil has been evaluated for prophylaxis of malaria in 6 clinical trials. In the 4 placebo-controlled trials for semi-immune residents or nonimmune migrants, the prophylaxis success rates in the atovaquone–proguanil and placebo arms ranged from 98% to 100% and 48% to 82%, respectively. The prophylaxis with success rates were similar among the 2 arms when atovaquone–proguanil was compared with other antimalarial regimens in nonimmune travelers. Atovaquone–proguanil was well tolerated in these clinical trials.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:</jats:title>\n                    <jats:p>Atovaquone–proguanil is a safe and effective alternative to current recommended regimens for prophylaxis and treatment of malaria.</jats:p>\n                  </jats:sec>","journal":"Annals of Pharmacotherapy","year":2003,"id":622202,"datarank":0.5101796072493234,"base_score":3.4011973816621555,"endowment":3.4011973816621555,"self_citation_contribution":0.5101796072493234,"citation_network_contribution":0.0,"self_endowment_contribution":0.5101796072493234,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":29,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1607505,"name":"James R Salzman","orcid":null,"position":1,"is_corresponding":false},{"id":1607506,"name":"Mary HH Ensom","orcid":null,"position":2,"is_corresponding":false},{"id":1607504,"name":"Fawziah Marra","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Atovaquone–Proguanil for Prophylaxis and Treatment of Malaria","abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:</jats:title>\n                    <jats:p>To review the currently available information on atovaquone–proguanil for treatment and prophylaxis of malaria.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:</jats:title>\n                    <jats:p>A MEDLINE search was conducted from 1966 to February 2003 using key phrases Malarone, atovaquone, proguanil, and malaria. Further articles were identified from a manual search of the references of identified articles.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION:</jats:title>\n                    <jats:p>English-language studies with animal and human data evaluating preclinical pharmacology, human studies on pharmacokinetics, and clinical trials were evaluated. Relevant data were extracted from identified articles.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:</jats:title>\n                    <jats:p>Atovaquone–proguanil has been evaluated for treatment of acute, uncomplicated malaria caused by Plasmodium falciparum in 8 clinical trials. In these studies, treatment with atovaquone–proguanil led to a higher (87–100% vs. 72–88%) or equally effective (94–100% vs. 90–100%) cure rate than the comparator antimalarial agents. Atovaquone–proguanil has been evaluated for prophylaxis of malaria in 6 clinical trials. In the 4 placebo-controlled trials for semi-immune residents or nonimmune migrants, the prophylaxis success rates in the atovaquone–proguanil and placebo arms ranged from 98% to 100% and 48% to 82%, respectively. The prophylaxis with success rates were similar among the 2 arms when atovaquone–proguanil was compared with other antimalarial regimens in nonimmune travelers. Atovaquone–proguanil was well tolerated in these clinical trials.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:</jats:title>\n                    <jats:p>Atovaquone–proguanil is a safe and effective alternative to current recommended regimens for prophylaxis and treatment of malaria.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":3.4011973816621555,"endowment":3.4011973816621555,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"12921511","pmcid":null,"openalex_id":"https://openalex.org/W2117641352","authors":[],"funders":[],"total_grants":0,"fwci":2.7112,"citation_percentile":0.89702187,"influential_citations":0,"citation_trend":[{"year":2012,"count":2},{"year":2014,"count":2},{"year":2015,"count":1},{"year":2018,"count":2},{"year":2019,"count":1},{"year":2020,"count":1},{"year":2021,"count":1},{"year":2023,"count":1},{"year":2024,"count":1},{"year":2026,"count":1}],"oa_status":"closed","license":"https://journals.sagepub.com/page/policies/text-and-data-mining-license","oa_locations":[{"url":"https://journals.sagepub.com/doi/pdf/10.1345/aph.1C473","host_type":"publisher"},{"url":"https://journals.sagepub.com/doi/full-xml/10.1345/aph.1C473","host_type":"publisher"},{"url":"https://doi.org/10.1345/aph.1c473","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/12921511","host_type":"repository"}],"fields_of_study":["Malaria Research and Control","Travel-related health issues","Parasites and Host Interactions"],"mesh_terms":["Antimalarials","Proguanil","Clinical Trials as Topic","Drug Interactions","Drug Therapy, Combination","Humans","Naphthoquinones","Malaria, Falciparum","Atovaquone"],"keywords":["Proguanil","Atovaquone","Medicine","Malaria","Malaria prophylaxis","Clinical trial","Placebo","Pharmacology","Plasmodium falciparum","Internal medicine","Immunology","Pathology","Alternative medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T18:39:01.206844Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}